December 18, 2019 / 10:24 PM / a month ago

BRIEF-Arcus Biosciences Announces Two Randomized Clinical Studies To Advance Ab928, A Dual Adenosine Receptor Antagonist, Into Novel Combinations For Colorectal And Pancreatic Cancers

Dec 18 (Reuters) - Arcus Biosciences Inc:

* ARCUS BIOSCIENCES, IN COLLABORATION WITH GENENTECH, ANNOUNCES TWO RANDOMIZED CLINICAL STUDIES TO ADVANCE AB928, A DUAL ADENOSINE RECEPTOR ANTAGONIST, INTO NOVEL COMBINATIONS FOR COLORECTAL AND PANCREATIC CANCERS

* ARCUS BIOSCIENCES INC - ADDITIONAL FINANCIAL TERMS OF COLLABORATION WITH GENENTECH WERE NOT DISCLOSED

* ARCUS BIOSCIENCES INC - UNDER AGREEMENT, CO, GENENTECH IS SUPPLYING ITS RESPECTIVE ANTI-CANCER AGENT TO SUPPORT TRIAL AND JOINTLY FUNDING STUDIES Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below